The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats

Urologia Internationalis

Volumn 86, Issue 2, 2011, Pages 197-203

  Guzeloglu, Mehmet ^b   Yalcinkaya, Fatih ^a   Atmaca, Soner ^b   Bagriyanik, Alper ^b   Oktar, Suleyman ^a   Yuksel, Oguz ^a   Fansa, Iyad ^a   Hazan, Eyup ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Ischemia reperfusion injury; Kidney; Leukocyte infiltration; Rats; Tadalafil

Indexed keywords

ANTIOXIDANT; PLACEBO; TADALAFIL;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; KIDNEY HOMOGENATE; KIDNEY INJURY; KIDNEY ISCHEMIA; MALE; NEPHRECTOMY; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; REPERFUSION INJURY; SINGLE DRUG DOSE; TUBULAR ATROPHY;

ANIMALS; ANTIOXIDANTS; ATROPHY; CARBOLINES; INFLAMMATION; KIDNEY; LEUKOCYTES; MALE; OXIDANTS; PLACEBOS; RATS; RATS, WISTAR; REPERFUSION INJURY; TIME FACTORS; VASODILATOR AGENTS;

EID: 79952989004     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321927     Document Type: Article

References (31)

1. Torsello G, Reinecke P, Szabo Z, Sandmann W: The role of pharmacologic kidney protection in preventing post-ischemic renal failure in animal experiment. Zentralbl Chir 1993; 118: 412-419.
2. Ellenberger C, Schweizer A, Diaper J, et al: Incidence, risk factors, and prognosis of changes in serum creatinine early after aortic abdominal surgery. Intensive Care Med 2006; 32: 1808-1816. (Pubitemid 44607370)
3. Lien YH, Lai LW, Silva AL: Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. Life Sci 2003; 74: 543-552. (Pubitemid 37410347)
4. Riera M, Torras J, Herrero I, et al: Neutrophils accentuate renal cold ischemia-reperfusion injury. Dose-dependent protective effect of a platelet-activating factor receptor antagonist. J Pharmacol Exp Ther 1997; 280: 786-794. (Pubitemid 27171341)
5. Oruc O, Inci K, Aki FT, et al: Sildenafil attenuates renal ischemia reperfusion injury by decreasing leukocyte infiltration. Acta Histochem 2010; 112: 337-344.
6. Sandner P, Hütter J, Tinel H, et al: PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 2007; 19: 533-543. (Pubitemid 350059687)
7. Rosen RC, Kostis JB: Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92: 9M-18M. (Pubitemid 37386271)
8. Raheem AA, Kell P: Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. Patient Prefer Adherence 2009; 3: 99-104.
9. Rosano GM, Aversa A, Vitale C, et al: Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214-222. (Pubitemid 40126979)
10. Sesti C, Florio V, Johnson EG, et al: The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 2007; 19: 55-61. (Pubitemid 46067349)
11. du Toit EF, Rossouw E, Salie R, et al: Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 2005; 19: 23-31. (Pubitemid 40767769)
12. Salloum FN, Ockaili RA, Wittkamp M, et al: Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol 2006; 40: 405-411. (Pubitemid 43277842)
13. Kukreja RC, Ockaili R, Salloum F, et al: Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J Mol Cell Cardiol 2004; 36: 165-173. (Pubitemid 38202344)
14. Sesti C, Florio V, Johnson EG, et al: The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 2007; 19: 55-61. (Pubitemid 46067349)
15. Onal A, Astarcioǧlu H, Ormen M, et al: The beneficial effect of L-carnitine in rat renal ischemia-reperfusion injury. Ulus Travma Acil Cerrahi Derg 2004; 10: 160-167.
16. Erel O: A novel automated method to measure total antioxidant response against potent free radical reactions. Clin. Biochem 2004; 37: 112-119. (Pubitemid 38077161)
17. Weight SC, Bell PR, Nicholson ML: Renal ischemia-reperfusion injury. Br J Surg 1996; 83: 162-170.
18. Woolfson RG, Millar CG, Neild GH: Ischaemia and reperfusion injury in the kidney: current status and future direction. Nephrol Dial Transplant 1994; 9: 1529-1531. (Pubitemid 24344761)
19. Döslüoǧlu HH, Aktan AO, Yeǧen C, et al: The cytoprotective effects of verapamil and iloprost (ZK 36374) on ischemia/reperfusion injury of kidneys. Transpl Int 1993; 6: 138-142. (Pubitemid 23108610)
20. Singh D, Chander V, Chopra K: Protective effect of catechin on ischemia-reperfusion induced renal injury in rats. Pharmacol Rep 2005; 57: 70-76. (Pubitemid 40601543)
21. Kaminski KA, Bonda TA, Korecki J, et al: Oxidative stress and neutrophil activation - the two keystones of ischemia/reperfusion injury. Int J Cardiol 2002; 86: 41-59. (Pubitemid 35247882)
22. Degirmenci B, Acar M, Albayrak R, et al: Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound. Urol Int 2006; 77: 170-172. (Pubitemid 44195780)
23. Choi DE, Jeong JY, Lim BJ, et al: Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 2009; 297:F362-F370.
24. Teixeira CE, Priviero FB, Webb RC: Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 2006; 316: 654-661. (Pubitemid 43130992)
25. Eherer AJ, Schwetz I, Hammer HF, et al: Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002; 50: 758-764. (Pubitemid 34539035)
26. Dousa TP: Cyclic-3′ ,5′ -nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999; 55: 29-62. (Pubitemid 29004236)
27. Kotera J, Fujishige K, Omori K: Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 2000; 48: 685-693. (Pubitemid 30233192)
28. Chintala MS, Bernardino V, Chiu PJ: Cyclic GMP but not cyclic AMP prevents renal platelet accumulation after ischemia-reperfusion in anesthetized rats. J Pharmacol Exp Ther 1994; 271: 1203-1208. (Pubitemid 24382622)
29. Seftel AD: Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin. Cardiol 2004; 27:I14-I19. (Pubitemid 38445545)
30. Verit A, Savas M, Ciftci H, Aksoy N, Taskin A, Topal U: Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study. Int J Impot Res 2010; 22: 115-119.
31. Serarslan Y, Yönden Z, Ozgiray E: Protective effects of tadalafil on experimental spinal cord injury in rats. J Clin. Neurosci 2010; 17: 349-352.